Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-25

Clinical Trial Update: Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the timing of indomethacin to prevent post-ERCP pancreatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INDOMETHACIN (INDOMETHACIN)

Snippet

Sponsor: University of Alberta | Conditions: Acute Pancreatitis | Phase 4 | Status: COMPLETED